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NF-kB is a key transcriptional regulator involved in
inflammation and cell proliferation, survival, and
transformation. Several key steps in its activation
are mediated by the ubiquitin (Ub) system. One un-
characterized step is limited proteasomal processing
of the NF-kB1 precursor p105 to the p50 active
subunit. Here, we identify KPC1 as the Ub ligase
(E3) that binds to the ankyrin repeats domain of
p105, ubiquitinates it, and mediates its processing
both under basal conditions and following signaling.
Overexpression of KPC1 inhibits tumor growth likely
mediated via excessive generation of p50. Also,
overabundance of p50 downregulates p65, suggest-
ing that a p50-p50 homodimer may modulate
transcription in place of the tumorigenic p50-p65.
Transcript analysis reveals increased expression of
genes associated with tumor-suppressive signals.
Overall, KPC1 regulation of NF-kB1 processing
appears to constitute an important balancing step
among the stimulatory and inhibitory activities of
the transcription factor in cell growth control.
INTRODUCTION
The NF-kB family of transcription factors is involved in regulation
of a variety of genes that control the immune and inflammatoryresponse, cell survival and death, proliferation, and differentia-
tion. Recently—150 years after Rudolf Virchow discovered the
infiltration of tumors with leukocytes and proposed a linkage be-
tween chronic inflammation and malignant transformation—it
has been shown that themechanism(s) that underlies this linkage
is mediated largely by the NF-kB family of transcription factors
(Ben-Neriah and Karin, 2011; DiDonato et al., 2012). NF-kB is
overexpressed in numerous tumors. It upregulates expression
of anti-apoptotic genes such as IAPs, cell-cycle promoters,
and growth factors and their receptors (DiDonato et al., 2012).
Nevertheless, in some cases NF-kBwas shown to display strong
tumor-suppressive characteristics (Perkins, 2012; Pikarsky and
Ben-Neriah, 2006). For example, it is involved in regulation of
activation-induced apoptosis of T lymphocytes (Ivanov et al.,
1997) and in inducing cell-cycle arrest and cell death caused
by repression of Bcl2, XIAP, Bcl-XL, Cyclin D1, and c-Myc that
occurs after cell damage. The arrest and death are mediated
by p52 dimers (Barre´ et al., 2010; Barre´ and Perkins, 2007).
Also, it was shown that NF-kB1/ cells accumulate alkylator-
induced mutations, and NF-kB1/ mice develop more lym-
phomas following alkylating agent-induced DNA damage,
again suggesting that NF-kB1 can act as a tumor suppressor
(Voce et al., 2014).
The family members aremostly heterodimers where one of the
subunits—p52 or p50—is the product of limited, ubiquitin- and
proteasome-mediated processing of a longer (and inactive)
precursor, p100 or p105, respectively (Betts and Nabel, 1996;
Fan and Maniatis, 1991; Palombella et al., 1994). The other sub-
unit is typically a member of the Rel family of proteins (RelA-p65,
RelB, or c-Rel). At times, p50 and p52 can generate homodimersCell 161, 333–347, April 9, 2015 ª2015 Elsevier Inc. 333
that cannot act as transcriptional activators since they lack a
transactivation domain present in the Rel proteins. In unstimu-
lated cells, the NF-kB dimers are sequestered in the cytosol
attached to ankyrin repeats (ARs) of IkB inhibitory proteins
(IkB, Bcl3, p100, and p105). A broad array of extracellular signals
stimulate degradation of the IkB proteins, resulting in transloca-
tion of the dimers to the nucleus where they initiate different tran-
scriptional programs (Rahman and McFadden, 2011).
Proteasomal processing of p105 occurs under both basal con-
ditions and following stimulation and requires prior ubiquitination
(Cohen et al., 2004; MacKichan et al., 1996). One element that
was shown to be important in the processing is a long Gly-Ala
repeat in the middle of p105 that may serve as a proteasomal
‘‘stop signal’’ (Lin and Ghosh, 1996). In addition to processing,
p105 can also undergo complete degradation, releasing NF-kB
dimers anchored to its C-terminal ARs domain. Following stimu-
lation, p105 is phosphorylated on serine residues 927 and 932
by IkB kinase (IKKb) (Salmero´n et al., 2001). This modification
recruits the beta-Transducin Repeat Containing Protein (bTrCP)
E3 (Orian et al., 2000), resulting in complete degradation of the
molecule (Heissmeyer et al., 2001). The ligase(s) involved in
processing of p105 under basal conditions as well as following
stimulation has remained elusive.
In the present study, we identified KIP1 ubiquitination-promot-
ing complex (KPC) as the Ub ligase that is involved in both basal
and signal-induced processing of p105. KPC is a heterodimer
made of KPC1 (RNF123) and KPC2 (UBAC1). It was shown to
degrade the cyclin-dependent kinase inhibitor p27Kip1 in the
G1 phase of the cell cycle (Kamura et al., 2004). KPC1 is a
RING-finger protein that serves as the ligase. KPC2 interacts
with ubiquitinated proteins and with the proteasome via its two
Ub-associated domains and a Ub-like domain, acting as a shut-
tle that promotes the degradation of p27Kip1. It was also shown
to stabilize KPC1 (Hara et al., 2005).
RESULTS
Identification of KPC1 as the p105 Ub Ligase
One of the still missing links in the Ub-mediated activation
pathway of NF-kB is the identity of the ligase that ubiquitinates
p105, resulting in its proteasomal processing to the p50 active
subunit. To identify the ligase, we sequentially fractionated rabbit
reticulocyte lysate using different chromatographic principles
(Figure 1Ai). Each fraction along the different steps was moni-
tored for E3 activity in a cell-free reconstituted conjugation
assay containing in vitro translated 35S-labeled p105 as a sub-
strate (Figure 1Aii). To avoid ubiquitination by the bTrCP ligase,
we used p105S927A mutant that cannot be phosphorylated
by IKKb and therefore cannot bind this E3. Employing mass
spectrometric analysis, peptides derived from the KPCUb ligase
were identified in active fractions along the three last chromato-
graphic steps. In the last step of purification (heparin), we identi-
fied 58 KPC1 peptides and seven KPC2 peptides covering
43.21% and 19.8% of the open reading frames, respectively
(Figure 1B). Because of lack sequence information on rabbit
KPC2, we used the sequence of the mouse protein to demon-
strate the coverage map. The changes between the two species
are negligible (but shown).334 Cell 161, 333–347, April 9, 2015 ª2015 Elsevier Inc.To test directly the role of KPC in p105 ubiquitination and
processing, we established a cell-free conjugation assay using
labeled p105 as a substrate and purified KPC1 or its catalytically
inactive species (mutated in the RING domain) KPC1I1256A as
the ligase. The wild-type (WT) ligase catalyzed conjugation of
p105, whereas the inactive ligase did not (Figure 2A). It appears
that KPC1 activity is specific to p105, as it scarcely modifies
p100 that is highly homologous to p105 and also undergoes
limited proteasomal processing, most probably by a different
ligase (Figure S1A).
To demonstrate the ability of KPC1 to modify p105 in cells, we
overexpressed Flag-p105 along with HA-Ub in HEK293 cells, in
which KPC1 was either silenced (Figure 2B, lane 1), or over-
expressed (Figure 2B, lanes 2 and 3). Immunoprecipitation of
p105 revealed that it is sparsely ubiquitinated in the absence of
the ligase, and ubiquitination is increased significantly following
overexpression of KPC1 (Figure 2Bi; immunoprecipitation [IP],
compare lanes 1 and 2). Furthermore, we found that p105
binds to KPC1 and co-immunoprecipitates with it (Figure 2Biii;
IP, lane 2). In addition, we demonstrated that endogenous
KPC1 interacts with endogenous p105 (Figure S1B).
KPC1 Promotes Basal and Signal-Induced Processing
of p105
To demonstrate the involvement of KPC1 in p105 processing, we
silenced its expression in cells using small interfering RNA
(siRNA). As can be seen in Figure 2C, the silencing of KPC1
decreased the amount of p50 generated from p105. In a different
experiment, we expressed in HEK293 cells FLAG-p105 along
with Myc-KPC1 or Myc-KPC1I1256A. Less p50 was generated
in the presence of the KPC1 mutant (Figure S1C).
As noted, processing of p105 occurs also following stimula-
tion. It was interesting to study whether KPC1 can promote
p105 processing under these conditions as well. Therefore, we
tested the generation of p50 from p105 following expression of
constitutively active IKKb (IKKbS176,180E) in the presence
(endogenous) or absence (silenced) of KPC1. As expected, the
stimulation increased theprocessing of p105 (compare Figure 2D
to Figure 2C; control siRNA). Silencing of KPC1 significantly
decreased the generation of p50 following stimulation, strongly
suggesting a role for KPC1 in signal-induced processing (Fig-
ure 2D). It is known that under the influence of the kinase, the
precursor was not only processed but also degraded to a sig-
nificant extent (compare Figure 2D to Figure 2C and note in
particular the decreasing amount of p105 + p50 remained along
time following stimulation). It should be noted that the degrada-
tion rate of p105 following stimulation was significantly higher
in cells that lack KPC1 (Figure 2D). It is possible that the process-
ing of p105 mediated by KPC1 and its degradation mediated
by bTrCP occur in parallel. When one process is inactivated,
the other becomes dominant. The influence of KPC1 on signal
induced-processing of p105 appears to be specific, as its
silencing does not affect the processing of p100 following
NF-kB-inducing kinase (NIK) expression (Figure S1D).
In all these experiments, we used exogenously expressed
p105. To demonstrate the effect on endogenous p105, we
used the human haploid cell line HAP1 in which the single allele
of KPC1 or KPC2 were knocked out using the Crispr-CAS
Figure 1. Purification and Identification of the p105 Ub Ligase
(A) (i) Scheme of the chromatographic resolution of Fraction II monitoring the E3 ligating activity toward p105. Numbers represent salt concentrations (M) or
molecular weight (kDa) at which the ligating activity was eluted from the respective columns. Fr II, Fraction II. (ii) E3 conjugating activity profile along the fractions
resolved by the Superdex 200 gel filtration column. In vitro translated and 35S-labeled p105S927A was ubiquitinated in a reconstituted cell-free system in the
presence of the resolved fractions.
(B) (i) Peptide coveragemap of rabbit KPC1. The peptides were identified throughmass spectrometric analysis of the E3-containing fractions resolved by the last,
Heparin-based column. (ii) Peptide coverage map of mouse KPC2. The peptides were identified through mass spectrometric analysis of the E3-containing
fractions resolved by the last, Heparin-based column. Residues marked in bold and italics denote differences in sequence between mouse and rabbit.technology. Elimination of KPC1 or KPC2 (that stabilizes KPC1
[Hara et al., 2005]; note that removal of KPC2 results in a signif-
icant decrease in the level of KPC1; Figure 2E) decreased
the generation of p50 both in the presence or absence of TNFa(Figure 2E). In contrast, the level of p65 was not affected. The
finding that p50 is still present, albeit in a decreased level, in
the KPC1 KO cells, may be due to the activity of another, yet
to be identified ligase, and/or to co-translational processing ofCell 161, 333–347, April 9, 2015 ª2015 Elsevier Inc. 335
(legend on next page)
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the nascent peptide that occurs before completion of the p105
precursor synthesis (Lin et al., 1998). It should also be noted
that the effect of KPC1 on p50 generation is significantly more
pronounced in tumors growing in mice than in cultured cells
(see below).
Our finding that KPC1 mediates processing under both basal
and stimulated conditions prompted us to dissect the mecha-
nism involved. We monitored the interaction between KPC1
and p105 under basal and stimulated conditions and found
that expression of constitutively active IKKb results in increased
interaction between the two as assayed by co-immunoprecipita-
tion (Figures 2F and S1E). The finding that the interaction of
p105S927A with KPC1 is not affected by IKKb (Figure 2Fi, lanes
4 and 5) attests to the specificity of the effect of IKKb in phos-
phorylating a specific Ser residue (927) in p105. As expected,
we found that ubiquitination of phosphorylated p105 by KPC1
is stronger compared to that of the non-phosphorylated species
(Figure S1F).
To further confirm that KPC1 interacts more efficiently with
phosphorylated p105, we designed an experiment in which we
competed on the binding of p105 to the ligase with a synthetic
phosphorylated peptide derived from the p105 IKKb-phos-
phorylation site. The phosphorylated peptide inhibited ubiquiti-
nation of p105 by KPC1 to a larger extent compared with itsFigure 2. p105 Is a Substrate of KPC1 in a Cell-free System and in Cel
(A) Ubiquitination of in vitro translated and 35S-labeled p105 by Fraction II and p
stituted cell-free system. Fr II, Fraction II.
(B) KPC1 ubiquitinates p105 in cells. HEK293 cells that were transfected with si
transfected with cDNAs coding for FLAG-p105 (lanes 1 and 2), HA-Ub (lanes
immunoprecipitated from the cell lysates using immobilized anti-FLAG (IP; lanes 1
KPC1 was visualized using a specific antibody to the protein (Biii). Ten percent of
HA-Ub or Myc-KPC1, using anti-HA (Bi), anti-FLAG (Bii), or anti-KPC1 (Biii), resp
(C) Silencing of KPC1 affects basal processing of p105. HEK293 cells were transfe
24 hr, cells were transfected with cDNAs coding for FLAG-p105. Processing of p10
the sum of p50 + p105 at time zero (in order to disregard degradation of p105 i
(reflecting degradation along time) was calculated as the sum of p50 + p105 mea
multiplied by 100%.
(D) Silencing of KPC1 inhibits signal-induced processing of p105. HEK293 cells we
4–6). After 24 hr, cells were transfectedwith cDNAs coding for FLAG-p105 and IKK
under C and D), cycloheximide was added for the indicated times, and cells were
KPC1 or anti-actin. Processing and degradation were assessed as described und
(E) Deletion of KPC1 or KPC2 genes inhibits basal and TNFa-induced processing
knocked out for the genes coding for KPC1 or KPC2. The lysates were resolved vi
KPC2, anti-p65, or anti-actin. The amount of p105 processed was calculated as
100%.
(F) The interaction between p105 and KPC1 increases following signaling. HEK29
FLAG-p105S927A (lanes 4 and 5) along with Myc-KPC1 (lanes 1–5) and FLAG-I
FLAG-p105S927A were immunoprecipitated from the cell lysate using immobiliz
(Fi). Immunoprecipitated p105s were visualized using anti-FLAG (Fii).
(G) A phosphorylated peptide corresponding to the signaled sequence in p105
uitinated by purified KPC1-FLAG-TEV-6xHIS (lanes 2–9) in a reconstituted cell-fre
sequence of p105 (lanes 6–8), or in the presence of its non-phosphorylated cou
mained following addition of increasing concentrations of the peptides (compare
(H) KPC2 attenuates ubiquitination of p105 by KPC1. Ubiquitination of in vitro trans
or absence of HIS-KPC2 was carried out in a cell-free reconstituted system.
(I) KPC2 attenuates processing of p105 in cells. HEK293 cells were transfected w
cells were transfected with cDNAs coding for FLAG-p105 and generation of p50
under (C).
(J) KPC1 modifies lysine residues in the C-terminal segment of p105. In vitro-tran
ubiquitination by purified KPC1-FLAG-TEV-6xHIS in a reconstituted cell-free sys
See also Figures S1 and S2.non-phosphorylated species, both in a crude system and in a
system made of purified components (Figures 2G and S1G,
respectively).
Role of KPC2 in KPC1-Mediated p105 Ubiquitination
and Processing
At that point, it was important to study the role of KPC2, the
partner of KPC1 in the heterodimeric ligase complex, in p105
modification and processing. We noted that its addition to a
reconstituted cell-free systemdecreases significantly the ubiqui-
tination of p105 by KPC1 (Figure 2H). This was true also when
p105 was purified by a specific antibody, ruling out a possible
effect of other components present in the mixture in which the
labeled p105 was translated (Figure S2Ai). To rule out that the
reduced ubiquitination of p105 in the presence of KPC2 is due
to a possible deubiquitinating activity of the protein, we added
it to the cell-free ubiquitination system after KPC1, when most
of the ubiquitination reaction was completed. It had no effect
on the conjugates pattern (Figure S2Aii). The interference of
KPC2 in chain formation appears to be specific to KPC1 and
p105, as it did not affect the ligase activity of E6-AP toward
RING1BI53S (Zaaroor-Regev et al., 2010) (Figure S2B).
Importantly, in correlation with the suppressive effect of KPC2
on KPC1-mediated ubiquitination of p105, silencing of KPC2ls, Both under Basal Conditions and following Signaling
urified KPC1-FLAG-TEV-6xHIS or KPC1I1256A-FLAG-TEV-6xHIS in a recon-
RNA to silence KPC1 (lane 1) or with control siRNA (lanes 2 and 3), were also
1–3), and Myc-KPC1 (lanes 2 and 3). FLAG-p105 and its conjugates were
–3), resolved via SDS-PAGE, and visualized using anti-HA (Bi) or anti-FLAG (Bii).
total cell lysates (TCL; lanes 1–3) were analyzed for expression of FLAG-p105,
ectively. IP, immunoprecipitation; WB, western blot.
cted with control siRNA (lanes 1–3) or siRNA to silence KPC1 (lanes 4–6). After
5 was calculated as the ratio between the amount p50 at the specified time and
n our calculations), multiplied by 100%. The amount of p50 + p105 remained
sured at the relevant time point, divided by the sum of p50 + p105 at time zero,
re transfected with control siRNA (lanes 1–3) or siRNA that targets KPC1 (lanes
bS176,180E. Twenty-four hours after transfection (in the experiments depicted
lysed, resolved via SDS-PAGE, and proteins visualized using anti-FLAG, anti-
er (C). Chx, cyclohexamide. Actin was used to ascertain equal protein loading.
of endogenous p105. Lysates were prepared from HAP1 control or HAP1 cells
a SDS-PAGE, and proteins were visualized using anti-NF-kB1, anti-KPC1, anti-
the ratio between the generated p50 and the sum of p50 + p105, multiplied by
3 cells were transfected with cDNAs coding for FLAG-p105 (lanes 2 and 3) or
KKb (lanes 2 and 4) or FLAG-IKKbS176,180E (lanes 3 and 5). FLAG-p105 and
ed anti-FLAG (lanes 1–5), and the bound KPC1 was visualized with anti-KPC1
inhibits its ubiquitination. In vitro translated and 35S-labeled p105 was ubiq-
e system in the presence of a phosphorylated peptide derived from the signaled
nterpart (lanes 3–5). Presented is the change (in %) of unconjugated p105 re-
d to a system to which a peptide was not added; lane 2).
lated and 35S-labeled p105 by purified KPC1-FLAG-TEV-6xHIS in the presence
ith control siRNA (lanes 1–3) or siRNA to silence KPC2 (lanes 4–6). After 24 hr,
was monitored 24 hr later. Processing of p105 was calculated as described
slated and 35S-labeled WT and the indicated p105 mutants were subjected to
tem.
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Figure 3. KPC1-Dependent Ubiquitination and Processing of p105 Require the ARs of p105
(A) Schematic representation of p105 domains. Numbers denote the respective residue along the protein sequence. RHD, Rel homology domain; NLS, nuclear
localization signal; GRR, glycine rich repeat; AR, ankyrin repeats (all six of them are marked).
(B) The ARs-containing C-terminal half of p105 is ubiquitinated by KPC1. In vitro-translated and 35S-labeled p105, p105D501-969 or p105D1-434 were subjected
to ubiquitination by purified KPC1-FLAG-TEV-6xHIS in a reconstituted cell-free system.
(C) The ARs of p105 are essential for binding of KPC1 and for its ubiquitination by the ligase in cells. HEK293 cells that were transfected with siRNA to silence
KPC1 (lanes 1 and 2) or with control siRNA (lanes 3–5), were also transfected with cDNAs coding for FLAG-p105 (lanes 1 and 3), p105D544-803 (lanes 2 and 4),
HA-Ub (lanes 1–5), and Myc-KPC1 (lanes 3–5). The different FLAG-p105 species and their conjugates were immunoprecipitated from the cell lysates by
immobilized anti-FLAG (IP; lanes 1–5).
(D) KPC1 interacts with a single AR in p105. HEK293 cells were transfected with cDNAs coding for FLAG-p105 (lane 2), FLAG-p105D544-803 (lane 3), or FLAG-
p105D574-803 (lane 4), along with Myc-KPC1 (lanes 1–4). The different FLAG-p105 species were immunoprecipitated from the cell lysates using immobilized
anti-FLAG (IP; lanes 1–4).
(legend continued on next page)
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increased the formation of p50 (Figure 2I). That, despite the fact
that the short-term silencing reduced partially the level of KPC1
via its effect (or absence thereof) on the stabilization of the ligase
(Figure 2I; note the change in the level of KPC1 following KPC2
silencing).
Identification of the Ub Anchoring Sites on p105
Modified by KPC1
We have already shown that multiple lysines in the C-terminal
segment of p105 are required for its ubiquitination and process-
ing (Cohen et al., 2004; Kravtsova-Ivantsiv et al., 2009) in
crude extracts. It was therefore important to show that this is
true also for KPC1. Progressive removal of all lysine residues
from the C-terminal segment (Figure S2C) resulted in corollary
decrease in conjugation of p105 by KPC1 in a cell-free assay
(Figure 2J) and in processing of the precursor in cells
(Figure S2D).
The C-Terminal ARs of p105 Are Necessary for Its
Interaction with KPC1 and for Its Subsequent
Ubiquitination and Processing
p105 harbors several domains: REL homology domain (RHD),
nuclear localization signal (NLS), and a glycine rich repeat
(GRR) in its N-terminal segment, and ARs, death domain (DD),
and a PEST (proline, glutamate, serine, and threonine) sequence
in the C-terminal segment (Figure 3A). We examined which of
these domains is necessary for ubiquitination by KPC1. As can
be seen in Figure 3B, removal of the C-terminal segment
abolished altogether conjugation in a cell-free system, whereas
removal of the N-terminal segment had no effect. Subsequently
we found that removal of all six ARs (p105D544-803) affected
significantly the ubiquitination of p105 by KPC1 (Figure S3A,
compare lanes 2 and 12). Partial deletion of the repeats affected
conjugation only slightly (compare lane 2 to lanes 4, 6, 8, and 10).
Similar results were obtained in experiments carried out in
cells. Overexpression of KPC1 increased the ubiquitination
of WT p105, but much less so of p105 that lacks all its ARs
(Figure 3Ci; IP, compare lane 4 to lane 3). Importantly, in parallel,
we observed also a decrease in the interaction between the
ARs’-truncated p105 and its ligase compared to WT p105
(Figure 3Ciii; IP, compare lanes 4 and 3).
To rule out the possibility that the decrease in ubiquitination of
p105 that lacks all its ARs is due to removal of the eight lysine
residues in the repeats, we generated a mutant p105 in which
all these lysines were substituted by arginines. The ubiquitination
of the K to R mutant as well as its interaction with KPC1, were
similar to that of WT p105 (Figures S3Bi and ii, respectively).
An interesting question relates to the number of ARs necessary
for ubiquitination and processing of p105. We constructed a(E) p105 that lacks its ARs is processed less efficiently in a cell-free system. The
system in the presence or absence of Fraction II as indicated. Fr II, Fraction II.
(F) Deletion of the ARs of p105 affects both its basal and signal-induced proc
FLAG-p105D544-803, FLAG-p105S927A, or FLAG-p105S927AD544-803 along w
In (C), (D), and (F), proteins were resolved via SDS-PAGE, blotted onto nitrocellul
detected using anti-KPC1, and Ub conjugates were detected using anti-HA. Te
proteins. The SDS-PAGE-resolved labeled proteins in the experiments shown in
as described under Figure 2E.
See also Figure S3.p105 mutant where all ARs except one have been deleted
(p105D574-803). The single remaining AR was sufficient to
bind KPC1 and to promote processing similar to that observed
for WT p105 (Figure 3D). Thus, it appears that the ARs are redun-
dant with relation to binding of KPC1.
Last, it was important to demonstrate whether the ARs-depen-
dent ubiquitination increases the processing of p105. As can be
seen in Figure 3E, mutant p105 that lacks all ARs, is processed
much less efficiently compared to the WT species and to one
lacking only some of the repeats (compare lane 12 to lanes 2,
4, 6, 8, and 10). A similar result was obtained also in cells (Fig-
ure 3F, lanes 1 and 2). Mutant p105 in which all lysine residues
in the ARs were substituted with arginines (FLAG-p105K8R), is
processed similarly to WT p105 (Figure S3C, lane 3), strongly
suggesting that the ARs are required for the binding, ubiquitina-
tion, and processing of p105, but do not serve as ubiquitination
sites essential for processing.
It appears that the ARs are also involved in signal-induced
processing of p105, as their removal significantly decreased
IKKb-mediated generation of p50 (Figure 3F, compare lane 4
to lane 3). As expected, FLAG-p105S927A and FLAG-
p105S927AD544-803 did not respond to IKKb-mediated phos-
phorylation (Figure 3F, lanes 7 and 8).
Overexpression of KPC1 or p50 Suppresses
Tumor Growth
Since NF-kB dimers are known to affect cell survival, prolife-
ration, and tumor progression, it was interesting to study the
outcome of KPC1 on cell growth. Initially, we monitored the
influence of overexpressed KPC1 on anchorage-independent
growth in MB-MDA 231, U2OS, and U87-MG cells, and found
that it inhibits colony formation by 36%, 32%, and 52%, respec-
tively, compared to controls (Figures 4A–4C). Importantly, this
effect was abrogated in cells overexpressing the inactive ligase
species KPC1I1256A, suggesting that the inhibitory effect is
due to the ligase activity (Figure 4C). Cells expressing p50
showed an even stronger inhibition of colony formation (73%
for both MB-MDA 231 and U87-MG cells; Figures 4A and 4C),
strongly suggesting that the effect of the ligase is mediated
through its activity on p105, resulting in excessive generation
of p50. Supporting the linkage is the finding that silencing of
p105 abrogated the strong suppressive effect of KPC1: the
number of colonies formed using cells that overexpress KPC1
in the absence of p105 was 7.5-fold larger than that formed in
its presence (Figure 4D). It was important to study whether the
growth suppressive effect of KPC1 and p50 is not due to induc-
tion of apoptosis. Thus, we stained U87-MG cells that overex-
press these proteins for cleaved caspase 3. As can be seen in
Figure S4, we could not detect the apoptotic marker. For thatdifferent 35S-labeled p105 species were processed in a cell-free reconstituted
essing. HEK293 cells were transfected with cDNAs coding for FLAG-p105,
ith either GFP or IKKb as indicated.
ose membrane, and p105 and p50 were detected using anti-FLAG, KPC1 was
n percent of the total cell lysates (TCL) were analyzed for the expression of
(B) and (E) were visualized using PhosphorImaging. Processing was assessed
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Figure 4. KPC1 and p50 Suppress Anchorage-Independent Growth of Cells
Suppression of colony formation by overexpressed KPC1 or p50 in MDA-MB 231 (Ai), U2OS (Bi), and U87-MG (Ci and Di) cells. Cells were stably transfected with
V0, or with cDNAs that code for Myc-KPC1, Myc-KPC1I1256A or FLAG-p50, or with cDNA coding for Myc-KPC1 along with control shRNA or shRNA to silence
p105, as indicated, and were seeded on soft agar plates. After 3 weeks, the colonies were stained with 0.05% crystal violet. Data derived from five experiments
(±SEM) are presented graphically. Expression of KPC1, KPC1I1256A, p50, and p105 is shown in (Aii), (Bii), (Cii), and (Dii).
See also Figure S4.
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experiment, it was also important to demonstrate that the sup-
pressive effect of KPC1 and p50 is not due to some non-specific
effect of the overexpression of the proteins. The unleashing of
growth in the presence of overexpressed KPC1 but in the
absence of p105 (Figure 4D), strongly suggests that the effect
of KPC1 is indeed specific.
These observations prompted us to study the effect of KPC1 in
a tumor model in mice. We generated xenografts stably overex-
pressing V0, KPC1, KPC1I1256A, or p50. Both the growth rate
and weights of tumors expressing KPC1 and p50 were signifi-
cantly smaller compared to those that harbor V0 or KPC1I1256A
(Figures 5Ai and 5Aiii for xenografts derived from U87-MG cells,
and Figure 5Aii for xenografts derived from MDA-MB 231 cells).
Importantly, in tumors that overexpress KPC1, the level of p50 is
significantly higher compared with tumors that express V0 (Fig-
ure 5Aiv), suggesting again a direct linkage between the KPC1
ligase activity and increased generation of p50. Interestingly,
in tumors that overexpress KPC1 or p50, we also observed a
significant decrease in the level of p65 (Figure 5Aiv). This finding
raises the possibility that a different NF-kB transcription factor
is generated under the influence of KPC1, possibly a p50 homo-
dimer (see Discussion). To demonstrate that there are indeed
changes in NF-kB species in human tumor xenografts overex-
pressing KPC1 and p50, we used electrophoretic mobility shift
assay (EMSA) to monitor the activity of the transcription factor.
As can be seen in Figure S5A, there is a significant decrease in
the ability of ‘‘canonical’’ NF-kB to bind its consensus DNA
sequence following overexpression of KPC1 and even more so
following overexpression of p50.
Of note, all the effects on tumor growth (reduction in colony
formation, tumor growth rate, and weight) were more prominent
in p50-expressing tumors than in their KPC1-overexpressing
counterparts. This is not surprising, as p50 is the product of
KPC1 activity, and its direct expression has a stronger effect.
The functional linkage between KPC1 and p50 can also be
observed in staining of specific proliferation and differentiation
markers in the mice-derived tumors. The overexpression of
KPC1, but not of KPC1I1256A, results in increased appearance
of nuclear NF-kB (Figure 5B), a significant decrease in the pro-
liferation marker ki-67, and an increase in the glial fibrillary acidic
protein (GFAP), a known glial cells differentiation marker.
Suspecting that KPC1 stimulates apoptosis, we looked for an
increase in cleaved caspase 3, however, there was no change
in the levels of the active enzyme compared to control sections.
Staining of p27Kip1—a suggested substrate of KPC1 (Kamura
et al., 2004)—did not show any change in the protein level (Fig-
ure 5B). This may be due to the differences in the systems
studied.
KPC1 Regulates Expression of a Subset of p50
Target Genes
Wenext analyzed the profile of gene expression in the tumors us-
ing RNA sequencing (RNA-seq) analysis of transcripts mapped
to the human genome (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE60530; Table S1). The altered gene expression
patterns revealed a strong similarity between overexpres-
sion of p50 and KPC1 in U87-MG xenografts (correlation of
0.51, p value < 10300; Figure 6Ai), with 48 downregulatedand 534 upregulated genes that were consistent and significant
in all replicates (Figure 6Aii; Table S2). The relative transcript
levels of selected genes that were shown to be significantly
upregulated and downregulated in RNA-seq analyses, was
corroborated by quantitative real-time PCR (qRT-PCR) (Fig-
ure S5B). Functional analysis revealed highly significant enrich-
ment in glycosylated and extracellular matrix proteins, and
upregulation of genes expressing proteins involved in cell-cell
and cell-substrate adhesion, regulation of cell migration, cell
junctions, vasculature development, wound healing, and cell-
cell signaling (Figure 6Aiii), suggesting a re-establishment
of ‘‘social’’ micro-environmental interactions in the p50- and
KPC1-overexpressing glioblastoma tumors (Bonavia et al.,
2011). Downregulated processes included a reduced response
to hypoxia required for maintaining glioblastoma stem cells
(Heddleston et al., 2009), as well as reduced positive regulation
of cell migration (Figure 6Aiii). Of the consistently changed
genes, 21 are known NF-kB targets (p value < 3.4 3 109;
http://www.bu.edu/nf-kb/gene-resources/target-genes/). To
further assess if the observed reduction in tumor size was the
consequence of a reduction in proto-oncogenes and/or of
an increased expression of tumor suppressor genes, we
gathered gene annotations from various sources. Enrichment
analysis on these gene annotations revealed a significant
(p value < 1.4 3 1018) increase in the expression of 40 tumor
suppressor genes, with no significant change in other classes
(Figure 6B).
Finally, we integrated functional annotation enrichment and
protein-protein interactions for the differentially regulated genes,
which revealed a dense network of upregulated genes revolved
around a few downregulated ones, such as interleukin-6 (IL-6),
interleukin-6 receptor (IL-6R), and vascular endothelial growth
factor A (VEGFA) (Figure 6C; Data S1). We included KPC1 and
NF-kB in this analysis to retrieve possible known interactions,
although KPC1 had no known interactions with any of the differ-
entially regulated genes. Closer look at the core interaction
network (Figure 6C, inset magnification) that included NF-kB is
most prominently annotated with ‘‘regulation of cell migration’’
genes. Most other core network genes are upregulated and
include many well-known tumor-suppressor genes.
Taken together, our findings strongly suggest a model of
KPC1/p50 driven glioblastoma tumor growth inhibition, that
centers around downregulated high mobility group protein
HMGI-C (HMGA2), lin-28 homolog A (LIN28), IL-6/IL-6R, and
VEGFA, and upregulated tumor suppressors, which in combina-
tion control the tumor-microenvironment as well as glioblastoma
stem cell maintenance.
Correlation between Expression of KPC1 and p50 in
Human Tumoral and Normal Tissues
Finally, we examined the relationship between KPC1 and p50
in human tumors and normal tissues. Immunohistochemical
staining of the two proteins (the two antibodies were shown to
be specific; see Figure S6) revealed a high correlation between
them in squamous cell carcinoma of head and neck (SCCHN,
52 sections; p value < 0.005; Figure 7Aii), breast cancer (105 sec-
tions; p value < 0.0001), and glioblastoma (192 sections;
p value < 0.0017) (Figure 7Ai). It should be emphasized thoughCell 161, 333–347, April 9, 2015 ª2015 Elsevier Inc. 341
Figure 5. KPC1-Mediated Excessive Gener-
ation of p50 Inhibits Tumor Growth
(A) Growth rates and weights of tumor xenografts
grown in mice, and derived from U87-MG (i) and
MDA-MB 231 (ii) cells expressing V0, Myc-KPC1,
and FLAG-p50. Data represent the mean of seven
xenografts ± SEM (iii) Tumors derived from U87-
MG cells 3 weeks after inoculation. (iv) Enhanced
generation of p50 and disappearance of p65 in
tumors that overexpress KPC1 and p50. Proteins
were resolved via SDS-PAGE, blotted onto nitro-
cellulose membrane, and detected using the
appropriate antibodies. Processing was assessed
as described under Figure 2E.
(B) Immunohistochemical staining of p50,
KPC1, ki-67, cleaved caspase 3, p27Kip1, and
GFAP in xenografts of U87-MG cells stably
expressing V0 (i), Myc-KPC1 (ii), FLAG-p50 (iii), or
KPC1I1256A (iv).
All scale bars, 100 mm. Tumors were grown in mice
and stained as described in the Experimental
Procedures.
See also Figure S5.
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Figure 6. RNA Analysis of Glioblastoma Xenografts Expressing KPC1 and p50
(A) (i) Gene expression pattern as revealed by RNA-seq of U87-MG xenografts overexpressing either KPC1 or p50. Shown is log2-transformed fold-change in
transcripts abundance against V0 control; dot size relates to the geometric mean significance over all experiments. (ii) Consistent downregulated and upregulated
(legend continued on next page)
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that the linkage may be tumor-specific and not common to all
patients with the ‘‘same’’ tumor.
To test the hypothesis that loss of KPC1 and nuclear p50 can
be involved in the pathogenesis of malignant transformation, we
analyzed the staining of the two proteins in SCCHN, breast can-
cer, and glioblastoma, and compared it to their staining in the
normal parallel tissue. We observed a strong decrease in tumor
samples stained for nuclear p50 compared to the healthy tissue
(Figure 7B). As for KPC1, we observed a significant decrease in
staining intensity (reflecting the amount of the protein) in
cancerous compared to normal tissue in both SCCHN and glial
cells, but not in breast cancer. Also, we noted a significant
decrease in the number of tumor samples stained for KPC1 in
SCCHN (Figure 7B). Taken together, these findings suggest
that nuclear p50 is indeed a tumor suppressor lost in many ma-
lignancies. At least part of this p50 loss may be due to loss of
KPC1 which catalyzes its formation, though this may not be
common to all tumors.DISCUSSION
The vast majority of substrates of the Ub proteasome system are
completely degraded. One intriguing and exceptional case is
that of the p105 precursor of NF-kB that can be either completely
degraded or processed in a limited manner to yield the p50
active subunit of the transcription factor. The ‘‘decision-making’’
mechanism resulting in one of the two distinct processes has re-
mained largely elusive. The bTrCP Ub ligase has been identified
as the tagging enzyme involved in complete degradation of
p105, whereas the ligase involved in processing has remained
unknown. We have now identified the KPC complex as the puta-
tive p105-processing ligase (Figures 1, 2, and 3).
Now that the two E3s involved in degradation and processing
of p105 have been identified, it is still not known why ubiquitina-
tion by one enzyme results in a completely different fate of p105
than ubiquitination by the other and what determines the timing
of the two reactions. It is possible that the two ligases catalyze
the formation of chains that differ in their anchoring sites, length,
and/or internal linkages. These, in turn, affect the recognition
and mechanism of action of the 26S proteasome. As for timing,
it can be that different physiological conditions and/or the
degree of saturation of the ARs with bound p50s are involved
in the ‘‘decision-making’’ process of whether the molecule will
be processed or destroyed completely.
Studying the biological implications of manipulating KPC1
revealed that it suppresses anchorage-independent growth in
a manner that is dependent on its ligase activity and the pres-
ence of p105. A corollary strong tumor-suppressive effect was
demonstrated in xenografts of human tumors (Figures 4, 5, andgenes in the xenografts. Dot sizes are as in (i). (iii) Selected annotation clusters mo
respectively).
(B) (i) Enrichment analysis of consistently upregulated and downregulated transc
differences for all tumor suppressors (blue) and proto oncogenes (red) from (i). G
shown.
(C) Integrated analysis of functional annotation clusters and known functional an
downregulated genes (green and red, respectively). NF-kB is shown in blue, and a
See also Figure S5, Tables S1 and S2, and Data S1.
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an entire set of tumor suppressors, some of them like the
brain-specific protein cell adhesion molecule 3 (CADM3) (Gao
et al., 2009), was found inactivated in glioblastoma.
An important question relates to the transcriptionalmechanism
by which KPC1 and p50 exert their tumor-suppressive effect. An
obvious assumption is that the stoichiometric excess of p50
generatedbyKPC1wouldgeneratemostlyp50-p50homodimers
rather than the ‘‘canonical’’ tumorigenic p50-p65 heterodimers.
In line with this finding is also the observation that p65 level is
decreased in KPC1-overexpressing as well as in p50-overex-
pressing xenografts (Figure 5Aiv). It appears that each dimer of
NF-kB family hasuniqueandevenopposingbiological function(s)
and regulates a distinct subset of downstream genes (Siggers
et al., 2012). p50 homodimer is supposed to act as a transcrip-
tional repressor because it does not contain a transactivation
domain (May and Ghosh, 1997). However, studies in vitro have
shown that p50 homodimer can interact with different transcrip-
tional modulators, such as Bcl-3 (Fujita et al., 1993), p300 (Deng
and Wu, 2003), or HMGA1/2 (Perrella et al., 1999) that are
involved inchromatin remodeling.Disproportionatep50mayshift
the composition of NF-kB dimers, resulting in overall tumor-sup-
pressive effect. Indeed, following overexpression of KPC1 or
p50, there is a decrease in the level of what is probably the ‘‘ca-
nonical’’ tumorigenic NF-kB (p50-p65; Figure S5A).
Importantly, we found a strong correlation between the
expression of KPC1 and that of p50 in human tumors (Figure 7A).
Moreover, we found a significant decrease in nuclear p50 and
KPC1 staining intensity in tumors compared to non-malignant
tissue (Figure 7B). This observation suggests that loss of
nuclear p50 may trigger malignant transformation. In line with
these findings are data collected in the Catalog Of Somatic
Mutations in Cancer (COSMIC) that show a significantly
greater number of common tumors (e.g., breast, lung, CNS,
and uterine cervix) with decreased expression of KPC1 tran-
scripts compared to those with high expression (http://cancer.
sanger.ac.uk/cosmic/gene/analysis?ln=RNF123&ln1=RNF123
&start=1&end=1315&coords=AA%3AAA&sn=&ss=&hn=&sh=
&samps=1001&expn=over&expn=under&id=4185).EXPERIMENTAL PROCEDURES
Materials, Plasmids, Expressed Proteins, and Cells
All materials (including plasmids and their construction, expression of proteins
and their purification, and cultured cells and their manipulation), are described
in the Extended Experimental Procedures.
Preparation and Fractionation of Crude Reticulocyte Lysate
Reticulocytes were induced in rabbits and lysates were prepared and fraction-
ated over DEAE cellulose to Fraction I (unabsorbed material) and Fraction IIst enriched for either up- or downregulated genes (above or below dashed line,
ripts for tumor suppressors and proto oncogenes annotations. (ii) Expression
ene names of the strongest differentially regulated cancer-related genes are
d physical protein-protein interactions among all consistently upregulated and
close-up of the core interaction network surrounding NF-kB (inset) is displayed.
Figure 7. Correlation between the Expression of KPC1 and p50 in Tumoral and Normal Human Tissues
(A) (i) Correlation between expression of KPC1 and p50 in tumors. Immunohistochemistry of KPC1 and p50 in serial sections from SCCHN, and glioblastoma
and breast cancer tissue arrays. P, p value. Analyses were carried out as described in the Experimental Procedures. (ii) Representative immunostaining of
SCCHN sections with anti-KPC1 or anti-p50. SI, staining intensity from 3 (strong positive) to 0 (negative). Arrowheads point to nuclear staining. Scale bars,
100 mm.
(B) Statistical analysis of p50 and KPC1 staining in normal and cancerous head and neck, glial and breast tissues. ‘‘Average of KPC1 SI’’ represents mean
of sample staining (number of samples is indicated under ‘‘Sample size’’). ‘‘KPC1 stained, %’’ and ‘‘nuclear p50, %’’ represent percent of samples stained
for KPC1 or nuclear p50. P, p value. The p value reflects the significance of difference between staining of normal and cancer tissue. SI, staining intensity;
N.S., non-significant.
See also Figure S6.(high salt eluate) as described (Hershko et al., 1983). Fraction II (200 mg) was
further resolved using different successive chromatographic methods as
described in the Extended Experimental Procedures.
In Vitro Translation
p105 or p100 were translated in vitro in the presence of L-[35S]methionine us-
ing the TNT T7 Quick reticulocyte lysate-based coupled transcription-transla-
tion kit according to the manufacturer’s instructions.
In Vitro Conjugation and Processing of p105
Ub conjugation and processing of 35S-labeled p105 were carried out in a
reconstituted cell-free system containing crude Fraction II as described(Kravtsova-Ivantsiv et al., 2009). For conjugation, 1 mg of purified Kpc1-
FLAG-TEV-6xHIS, Kpc1I1256A-FLAG-TEV-6xHIS, or 6xHis-KPC2 were
added as indicated instead of Fraction II.
Ub Conjugates in Cells
HEK293 cells were transfected with control siRNA or siRNA against KPC1 as
described above. After 24 hr, the cells were transfected with cDNAs coding
for FLAG-p105 proteins along with cDNAs coding for HA-Ub and Myc-
KPC1, or with an empty vector. After additional 24 hr, the proteasome inhibitor
MG132 (20 mM) was added for 3 hr, and the cells were lysed with RIPA buffer
supplemented with freshly dissolved iodoacetamide and N-ethylmaleimide
(5 mM each) to inhibit deubiquitinating enzymes. p105 (both free andCell 161, 333–347, April 9, 2015 ª2015 Elsevier Inc. 345
ubiquitinated) and free p50 were immunoprecipitated with immobilized anti-
FLAG. The beads were washed five times with RIPA buffer and proteins
were resolved by SDS-PAGE. Free and conjugated p105 (and free p50) were
visualized using anti-FLAG.
Tumorigenicity
Cell-based (soft agar) and animal (mice xenografts) tumorigenicity assays are
described in the Extended Experimental Procedures.
RNA-Seq Analysis
RNA from U87-MG xenografts was isolated using RNA purification kit and
analyzed using the Illumina HiSeq 2500 analyzer. Identification and clustering
of the human genes are described in the Extended Experimental Procedures.
Immunohistochemistry and Statistical Analysis
The staining technique and statistical analysis of the staining data of SCCHN,
breast cancer, and glioblastomawere performed as described in the Extended
Experimental Procedures.
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